1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations
Year: 2023
Type: article
Source: Annals of Oncology
Institutions: Yale University, Smilow Cancer Hospital, Sarah Cannon, Tennessee Oncology, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of California, Irvine, Mayo Clinic, University of Virginia Cancer Center, Huntsman Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Florida Cancer Specialists & Research Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Arvinas (United States), Weill Cornell Medicine, Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Endocyte, Regeneron Pharmaceuticals, Exelixis, Huntsman Cancer Institute, Celldex Therapeutics, Clovis Oncology, Mirati Therapeutics, Incyte, Cardinal Health, Advanced Accelerator Applications, UroGen Pharma, MacroGenics, Invitae, Eisai, Astellas Pharma, Ipsen, Bavarian Nordic, Genentech, EMD Serono, Sanofi Genzyme, Pharmacyclics, Loxo Oncology, Foundation Medicine, Daiichi Sankyo Company, Daiichi Sankyo Europe
OpenAlex ID: W4387810293